Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
Q5148 Filgrastim-txid (nypozi) Nypozi 1 microgram Ancillary Therapy Immunostimulant Colony-Stimulating Factor No 2024 Mar 26, 2025 In Use
C9173 Filgrastim-txid (nypozi) Nypozi 1 mcg Ancillary Therapy Immunostimulant Colony-Stimulating Factor No 2024 Dec 17, 2024 Jul 9, 2025 In Use
J9266 Pegaspargase Oncaspar unspecified Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1996 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J9092 Cyclophosphamide Cyclophosphamide 2 g Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Jan 1, 1994 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan 1, 2000 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
J9184 Gemcitabine (avyxa) Avgemsi 200mg Chemotherapy Antimetabolite Pyrimidine Analog No 2025 Jan 1, 2026 In Use
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan 1, 2016 In Use
S0172 Chlorambucil Leukeran 2 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1957 Jan 1, 2002 In Use
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
C9449 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Apr 1, 2015 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
J9261 Nelarabine Arranon 50 mg Chemotherapy Antimetabolite Purine Analog No 2005 Jan 1, 2007 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 Jan 1, 2026 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
J9052 Carmustine (Accord) Carmustine 100mg Chemotherapy Alkylating Agent Nitrosurea No 2022 Dec 7, 2023 In Use
C9307 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Bispecific Antibody BCMA, CD3 No 2025 Jan 1, 2026 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
J9390 Vinorelbine Navelbine 10 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1994 Jan 1, 1996 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.